Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral...
Published in: | Malaria Journal |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2018
|
Subjects: | |
Online Access: | https://doi.org/10.1186/s12936-018-2593-x https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 |
_version_ | 1821839057764745216 |
---|---|
author | Matthew J. Grigg Timothy William Kim A. Piera Giri S. Rajahram Jenarun Jelip Ammar Aziz Jayaram Menon Jutta Marfurt Ric N. Price Sarah Auburn Bridget E. Barber Tsin W. Yeo Nicholas M. Anstey |
author_facet | Matthew J. Grigg Timothy William Kim A. Piera Giri S. Rajahram Jenarun Jelip Ammar Aziz Jayaram Menon Jutta Marfurt Ric N. Price Sarah Auburn Bridget E. Barber Tsin W. Yeo Nicholas M. Anstey |
author_sort | Matthew J. Grigg |
collection | Directory of Open Access Journals: DOAJ Articles |
container_issue | 1 |
container_title | Malaria Journal |
container_volume | 17 |
description | Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral artesunate (total target dose 12 mg/kg) daily for 3 days was conducted in patients with uncomplicated falciparum malaria and a parasite count < 100,000/µL admitted to 3 adjacent district hospitals in Sabah, East Malaysia. On day 3 and 4 all patients were administered split dose mefloquine (total dose 25 mg/kg) and followed for 28 days. Twenty-one kelch13 polymorphisms associated with P. falciparum artemisinin resistance were also evaluated in P. falciparum isolates collected from patients presenting to health facilities predominantly within the tertiary referral area of western Sabah between 2012 and 2016. Results In total, 49 patients were enrolled and treated with oral artesunate. 90% (44/49) of patients had cleared their parasitaemia by 48 h and 100% (49/49) within 72 h. The geometric mean parasite count at presentation was 9463/µL (95% CI 6757–13,254), with a median time to 50% parasite clearance of 4.3 h (IQR 2.0–8.4). There were 3/45 (7%) patients with a parasite clearance slope half-life of ≥ 5 h. All 278 P. falciparum isolates evaluated were wild-type for kelch13 markers. Conclusion There is no suspected or confirmed evidence of endemic artemisinin-resistant P. falciparum in this pre-elimination setting in Sabah, Malaysia. Current guidelines recommending first-line treatment with ACT remain appropriate for uncomplicated malaria in Sabah, Malaysia. Ongoing surveillance is needed southeast of the Greater Mekong sub-region. |
format | Article in Journal/Newspaper |
genre | Arctic |
genre_facet | Arctic |
geographic | Arctic |
geographic_facet | Arctic |
id | ftdoajarticles:oai:doaj.org/article:1c30bf558fcf4dba809bed709ab62968 |
institution | Open Polar |
language | English |
op_collection_id | ftdoajarticles |
op_doi | https://doi.org/10.1186/s12936-018-2593-x |
op_relation | http://link.springer.com/article/10.1186/s12936-018-2593-x https://doaj.org/toc/1475-2875 doi:10.1186/s12936-018-2593-x 1475-2875 https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 |
op_source | Malaria Journal, Vol 17, Iss 1, Pp 1-8 (2018) |
publishDate | 2018 |
publisher | BMC |
record_format | openpolar |
spelling | ftdoajarticles:oai:doaj.org/article:1c30bf558fcf4dba809bed709ab62968 2025-01-16T20:44:10+00:00 Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance Matthew J. Grigg Timothy William Kim A. Piera Giri S. Rajahram Jenarun Jelip Ammar Aziz Jayaram Menon Jutta Marfurt Ric N. Price Sarah Auburn Bridget E. Barber Tsin W. Yeo Nicholas M. Anstey 2018-12-01T00:00:00Z https://doi.org/10.1186/s12936-018-2593-x https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 EN eng BMC http://link.springer.com/article/10.1186/s12936-018-2593-x https://doaj.org/toc/1475-2875 doi:10.1186/s12936-018-2593-x 1475-2875 https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 Malaria Journal, Vol 17, Iss 1, Pp 1-8 (2018) Plasmodium falciparum Malaria kelch K13 Artemisinin-resistance Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2018 ftdoajarticles https://doi.org/10.1186/s12936-018-2593-x 2022-12-31T15:19:18Z Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral artesunate (total target dose 12 mg/kg) daily for 3 days was conducted in patients with uncomplicated falciparum malaria and a parasite count < 100,000/µL admitted to 3 adjacent district hospitals in Sabah, East Malaysia. On day 3 and 4 all patients were administered split dose mefloquine (total dose 25 mg/kg) and followed for 28 days. Twenty-one kelch13 polymorphisms associated with P. falciparum artemisinin resistance were also evaluated in P. falciparum isolates collected from patients presenting to health facilities predominantly within the tertiary referral area of western Sabah between 2012 and 2016. Results In total, 49 patients were enrolled and treated with oral artesunate. 90% (44/49) of patients had cleared their parasitaemia by 48 h and 100% (49/49) within 72 h. The geometric mean parasite count at presentation was 9463/µL (95% CI 6757–13,254), with a median time to 50% parasite clearance of 4.3 h (IQR 2.0–8.4). There were 3/45 (7%) patients with a parasite clearance slope half-life of ≥ 5 h. All 278 P. falciparum isolates evaluated were wild-type for kelch13 markers. Conclusion There is no suspected or confirmed evidence of endemic artemisinin-resistant P. falciparum in this pre-elimination setting in Sabah, Malaysia. Current guidelines recommending first-line treatment with ACT remain appropriate for uncomplicated malaria in Sabah, Malaysia. Ongoing surveillance is needed southeast of the Greater Mekong sub-region. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 17 1 |
spellingShingle | Plasmodium falciparum Malaria kelch K13 Artemisinin-resistance Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Matthew J. Grigg Timothy William Kim A. Piera Giri S. Rajahram Jenarun Jelip Ammar Aziz Jayaram Menon Jutta Marfurt Ric N. Price Sarah Auburn Bridget E. Barber Tsin W. Yeo Nicholas M. Anstey Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title | Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title_full | Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title_fullStr | Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title_full_unstemmed | Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title_short | Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
title_sort | plasmodium falciparum artemisinin resistance monitoring in sabah, malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance |
topic | Plasmodium falciparum Malaria kelch K13 Artemisinin-resistance Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
topic_facet | Plasmodium falciparum Malaria kelch K13 Artemisinin-resistance Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
url | https://doi.org/10.1186/s12936-018-2593-x https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 |